Moderna delivered doses of its vaccine candidate, mRNA-1273.351, specific against the SARS-CoV-2 variant first identified in the Republic of South Africa, to the US National Institutes of Health (NIH) for clinical study.
You learn it from the company.
Moderna announced further capital investments to increase the global production capacity of the Covid-19 vaccine: the production capacity planned for 2022 has increased to 1.4 billion doses, and the base plan for 2021 has increased to 700 million doses. and the company is working to supply up to 1 billion doses in 2021. This was announced by the same company, stressing that the new capital investments "will allow for additional production of the current Covid-19 vaccine and guarantee flexibility to deal with production. of potential vaccine boosters against variants ".
"To meet the increased demand for vaccine doses, we plan to produce 2 billion doses in 2021, more than 50% of the expected production of 1.3 billion doses. The interventions planned to increase our production capacities are well underway. ".
ANSA learns from the pharmaceutical company Pfizer who explains: "We are making progress on key initiatives: modification of production processes in the plant in Puurs, successfully completed; the BioNTech production site has received the production license and we will start production for EMA validation in February, according to previously announced plans ".
